EP Patent

EP0785927B1 — Novel benzoxazoles

Assigned to Euro Celtique SA · Expires 2003-08-27 · 23y expired

What this patent protects

Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regards to, e.g., PDE III inhibition.

USPTO Abstract

Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regards to, e.g., PDE III inhibition.

Drugs covered by this patent

Patent Metadata

Patent number
EP0785927B1
Jurisdiction
EP
Classification
—
Expires
2003-08-27
Drug substance claim
No
Drug product claim
No
Assignee
Euro Celtique SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.